Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares traded up 5.5% during trading on Monday . The stock traded as high as $16.64 and last traded at $16.17. 949,568 shares were traded during trading, an increase of 37% from the average session volume of 694,190 shares. The stock had previously closed at $15.32.

Several research analysts recently commented on the stock. Piper Jaffray Companies upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $14.00 to $33.00 in a report on Thursday, September 7th. JMP Securities upgraded shares of Intra-Cellular Therapies from a “market perform” rating to an “outperform” rating and set a $24.00 target price for the company in a report on Thursday, August 24th. ValuEngine upgraded shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a report on Friday, August 18th. Cowen and Company restated an “outperform” rating and set a $27.00 target price (up previously from $20.00) on shares of Intra-Cellular Therapies in a report on Friday, September 8th. Finally, SunTrust Banks, Inc. upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a report on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. Intra-Cellular Therapies presently has a consensus rating of “Buy” and an average target price of $25.00.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.53) EPS for the quarter, meeting analysts’ consensus estimates of ($0.53). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.06 million. Intra-Cellular Therapies had a negative net margin of 28,038.35% and a negative return on equity of 27.40%. The company’s revenue for the quarter was up 675.0% compared to the same quarter last year. During the same quarter last year, the company posted ($0.70) earnings per share. equities research analysts anticipate that Intra-Cellular Therapies Inc. will post -2.16 EPS for the current year.

In related news, major shareholder Alafi Capital Co Llc acquired 258,065 shares of the company’s stock in a transaction dated Monday, October 2nd. The shares were bought at an average cost of $15.50 per share, with a total value of $4,000,007.50. Following the completion of the transaction, the insider now directly owns 3,953,270 shares of the company’s stock, valued at $61,275,685. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Sharon Mates sold 18,750 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $15.75, for a total transaction of $295,312.50. Following the completion of the transaction, the chief executive officer now directly owns 1,107,457 shares in the company, valued at $17,442,447.75. The disclosure for this sale can be found here. 21.00% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. raised its position in shares of Intra-Cellular Therapies by 336.1% in the second quarter. Goldman Sachs Group Inc. now owns 580,770 shares of the biopharmaceutical company’s stock valued at $7,213,000 after purchasing an additional 447,586 shares during the period. First Midwest Bank Trust Division raised its position in shares of Intra-Cellular Therapies by 18.2% in the third quarter. First Midwest Bank Trust Division now owns 184,836 shares of the biopharmaceutical company’s stock valued at $2,917,000 after purchasing an additional 28,487 shares during the period. Fox Run Management L.L.C. bought a new position in shares of Intra-Cellular Therapies in the third quarter valued at about $390,000. Federated Investors Inc. PA raised its position in shares of Intra-Cellular Therapies by 113.3% in the second quarter. Federated Investors Inc. PA now owns 183,035 shares of the biopharmaceutical company’s stock valued at $2,273,000 after purchasing an additional 97,228 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in Intra-Cellular Therapies by 192.2% during the first quarter. Dimensional Fund Advisors LP now owns 124,622 shares of the biopharmaceutical company’s stock worth $2,025,000 after acquiring an additional 81,969 shares during the period. 61.10% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This news story was first reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another site, it was copied illegally and reposted in violation of US and international trademark and copyright law. The correct version of this news story can be viewed at https://www.watchlistnews.com/intra-cellular-therapies-inc-itci-trading-5-5-higher/1719920.html.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.